Answers are grounded in this paper and cite their sources.
WHAT IS KNOWN AND OBJECTIVE: Triazole antifungal-associated skin rash is rare. Data on cross-reaction triazole antifungals remain inconclusive and poorly defined. We report successful voriconazole challenge in a patient allergic to posaconazole. CASE SUMMARY: A 38-year-old female diagnosed with acute myeloid leukaemia and receiving chemotherapy treatment in our institution developed a maculopapular rash after receiving oral posaconazole for invasive fungal infection prophylaxis. Other potential causes that may have attributed to this response, such as other drugs that the patient was taking and infections, were excluded. Voriconazole, another triazole antifungal, was successfully substituted for posaconazole. WHAT IS NEW AND CONCLUSION: This is the first case report of a patient, with a history of posaconazole allergy, successfully challenged with voriconazole.
No takes yet. Share an insight, caveat, or question.
Weeraphon et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: